Cost-effectiveness of interferon in chronic myeloid leukemia: Analysis of four clinical studies

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 389-396

  Messori, A ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Chronic myeloid leukaemia; Cost effectiveness analysis; Interferon; Pharmacoeconomics

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA;

ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; LIFE EXPECTANCY; MAINTENANCE THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AREA UNDER CURVE; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; ENGLAND; FEMALE; GERMANY; HUMANS; INTERFERON-ALPHA; ITALY; JAPAN; LEUKEMIA, MYELOID, CHRONIC; MALE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; STATISTICS; SURVIVAL RATE;

EID: 0031745315     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008212411489     Document Type: Article

References (34)

1. Allan NC, Richards SM, Shepherd PCA, et al. UK Medical Research Council randomized multi-center trial of interferon-α-nl for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-7.
2. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon-α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-5.
3. Hehlman R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulphan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-77.
4. Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-16.
5. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736-44.
6. Kumar L, Gulati SC. Alpha-interferon in chronic myelogenous leukemia. Lancet 1995; 346: 984-6.
7. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-α therapy for chronic myelogenous leukemia. Am J Med 1995; 89: 402-11.
8. Mark DB, Hlatky MA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24.
9. Mark DB. Economic analysis methods and end-points. In Califf RM, Mark DB, Wagner B (eds): Acute Coronary Care in the Thrombolytic Era. St. Louis: Mosby 1995; 167-82.
10. Bennett WG, Inoue Y, Beck R et al. Estimates of the cost-effectiveness of a single course of interferon-α-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
11. Etchason J, Petz L, Keeler E et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332: 719-24.
12. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-6.
13. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321:807-12.
14. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111-6.
15. Messori A, Bonistalli L, Costantini M et al. Cost-effectiveness of adjuvant intraportal supportive therapy in colorectal cancer. J Clin Gastroenterol 1996; 23: 269-76.
16. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: A lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366-71.
17. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997; 33: 1373-9.
18. Messori A, Bonistalli L, Costantini M, Allerini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 275-81.
19. Varoli G. Matematica Finanziaria. Bologna: Patron 1990.
20. Messori A, Survival curve fitting using the Gompertz function: A methodology for conducting cost-effectiveness analyses on mortality data. Comput Meth Progr Biomed 1997; 52: 157-64.
21. Fine HA, Dear KBG, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-92.
22. Messori A, Brignola C, Trallori G et al. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994; 89: 692-8.
23. Bardelli F, Messori A, Rampazzo R et al. Effect of recombinant or lymphoblastoid α-interferon on ALT in patients with chronic hepatitis C or chronic non-A non-B hepatitis: A meta-analysis. Clin Drug Invest 1995; 9: 239-54.
24. Robinson R. Cost-effectiveness analysis. BMJ 1993; 307: 793-5.
25. Simes RJ. Confronting publication bias: A cohort design for meta-analysis. Stat Med 1987; 6: 11-29.
26. Pavol MA, Meyers CA, Rexer JL et al. Pattern of neurobehavioral deficits associated with interferon-α therapy for leukemia. Neurology 1995; 45: 947-50.
27. Sacchi S, Kantarjian H, O'Brien S et al. Immue-mediated and unusual complications during interferon-α therapy in chronic myeloid leukemia. J Clin Oncol 1995; 13: 2401-7.
28. Ring T, Krogh-Jensen M. Interferon-α for chronic myeloid leukemia. Lancet 1995; 344: 1370.
29. Kattan MW, Inoue Y, Giles FJ et al. Cost-effectiveness of interferon-α and conventional chemotherapy in chronic myeloid leukemia. Ann Intern Med 1996; 125: 541-7.
30. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of α-interferon alpha in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 2673-82.
31. Messori A, Becagli P, Trippoli S. Cost-effectiveness of interferon-α as maintenance therapy in chronic myelogenous leukemia. Ann Intern Med 1997; 126: 664-5.
32. Mahon FX, Fabères C, Montastruc M et al. High-response rate using recombinant interferon-i in patients with newly diagnosed chronic myeloid leukemia. Bone Marrow Transplant 1996; 17 (Suppl 3): S33-S7.
33. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995; 122: 254-9.
34. Chronic Myeloid Leukaemia Trialists' Collaborative Group. Interferon-α versus chemotherapy for chronic myeloid leukaemia: A meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89: 1616-20.